{"entity":{"id":"glumetinib","kind":"drug","name":"Glumetinib","aka":[],"tldr":"Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.","summary":"Haihe Biopharma's glumetinib (SCC244) was approved by the NMPA in 2023 for locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping, on the GLORY phase 2 trial. It joins savolitinib and vebreltinib as China's approved MET inhibitors, alongside capmatinib and tepotinib elsewhere. A phase 3 trial in MET-amplified gastric cancer with chemotherapy is registered.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Glumetinib","url":"https://clinicaltrials.gov/search?intr=SCC244"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","gastric","sclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06829459"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"SCC244","modality":"Oral selective MET tyrosine kinase inhibitor","mechanism":"A highly selective type I MET kinase inhibitor for tumours driven by MET exon 14 skipping or amplification.","approvals":[{"region":"CN","year":2023,"indication":"Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/glumetinib/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"trial":[{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/"},{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","route":"/trials/nct04270591/"},{"id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/"}]}}